The success of an ongoing pilot programme offering RSV vaccination to newborn infants provides hope in tackling the ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

With federal support, universities produce world-changing discoveries and the next generation of exquisitely well-trained ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Bob Kierlin built Fastenal into a billion-dollar industry leader. His true legacy isn’t just Fastenal’s growth — it’s the ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...